In doing so they might point to biologically relevant targets for new drugs and predictive diagnostics. Genes encode proteins, so identifying the genes and specific genetic variations that patients tended to share more often than healthy individuals should provide a foothold in the pathogenesis of disease. When he was recruited from Chicago to Harvard, Stefansson, he began to think that the genome might provide a better starting point than biology. He and his colleagues came to question even the accepted definition of multiple sclerosis (MS) as an autoimmune disease. Although publishing steadily, Stefansson was frustrated by the pace of progress and often by not knowing whether the proteins he was characterizing were involved in causing disease or the product of the disease process. The protein biology approach to this research involved trying to map complex processes using limited samples, mainly of brain tissue from deceased patients. Stefansson's academic work was focused on neurodegenerative disease. He is a board-certified neurologist and neuropathologist in both Iceland and the US. Since 2010, he has held a professorship in medicine at the University of Iceland. Stefansson resigned both positions in 1997 after founding deCODE and moving back to Reykjavik. While in Boston, he and his colleague Jeffrey Gulcher decided to return to Iceland to perform genetic studies to determine multiple sclerosis risk. In 1993 he was appointed professor of neurology, neuropathology and neuroscience at Harvard University and division chief of neuropathology at Boston's Beth Israel Hospital. There he completed residencies in neurology and neuropathology, and in 1983 joined the faculty. Academic career įollowing his internship at the National Hospital of Iceland, he went to the University of Chicago to work under Barry Arnason (coincidentally a Canadian of Icelandic descent). ![]() His favorite author is Isaac Bashevis Singer. He initially thought of becoming a writer, and attests to being a voracious reader. ![]() Stefansson says that he owes much to his brother, who suffers from schizophrenia. In June 2012, his daughter, Sólveig "Sóla" Káradóttir, married Dhani Harrison, son of the late George Harrison and his wife, Olivia Harrison. He was married to Valgerður Ólafsdóttir from 1970 until her death on 11 November 2021. He completed his secondary education at Reykjavik Junior College and received his M.D. He was the second youngest of the five children of Sólveig Halldórsdóttir and Stefán Jónsson, a radio personality, writer and democratic socialist member of parliament. Kari Stefansson was born in 1949 in Reykjavik, Iceland. This population approach has served as a model for national genome projects around the world and contributed to the realization of several aspects of precision medicine. His work has focused on how genomic diversity is generated and on the discovery of sequence variants impacting susceptibility to common diseases. ![]() In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome. This transaction does not require regulatory approval, and is expected to close before the end of the year.Kári Stefánsson (or Kari Stefansson born 6 April 1949) is an Icelandic neurologist and founder and CEO of Reykjavik-based biopharmaceutical company deCODE genetics. Kari Stefansson, founder and CEO of DeCode, which is based in Reykjavik, added: ‘We believe Amgen's focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients.’ This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programmes based on less well-validated targets.’ ‘This capability will enhance our efforts to identify and validate human disease targets. ‘DeCode has built a world-class capability in the study of the genetics of human disease,’ said Robert Bradway, president and CEO of Amgen. US biotechnology company Amgen has agreed to buy DeCode Genetics, a pioneer in human genetics research, for US$415m in cash to boost its aim to develop better targeted drugs.įounded in 1996, Icelandic firm DeCode has used the population of Iceland to identify genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer. Gains the ability to identify and validate disease targets in human populations
0 Comments
Leave a Reply. |